SCHEMBL20028050

SCHEMBL20028050

CCOC(=O)c1cc(C)nn1-c1cccc(CNC(=O)Cc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 4/20 0.47
CARM1 Q86X55 3/20 0.44
LMNA P02545 2/20 0.44
STAT1 P42224 1/20 0.44
P2RX7 Q99572 2/20 0.43
ERCC1 P07992 1/20 0.43
ERCC4 Q92889 1/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
PPP1CA P62136 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20027787 0.90 KMT2A (0.51) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL20028049 0.88 MAPT (0.54) MAPTALDH1A1CARM1P2RX7ERCC1
SCHEMBL20028524 0.88 KMT2A (0.60) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL20028491 0.87 KMT2A (0.51) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL20028694 0.87 KMT2A (0.51) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL22897256 0.86 KMT2A (0.50) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL18231857 0.83 KMT2A (0.47) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL29641667 0.83 KMT2A (0.47) KMT2AMAPTL3MBTL1ALDH1A1CARM1
SCHEMBL20027642 0.83 KMT2A (0.55) KMT2AMAPTL3MBTL1ALDH1A1LMNA
SCHEMBL20028059 0.82 MAPT (0.57) KMT2AMAPTL3MBTL1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885MAPT 562/4885L3MBTL1 3522/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 KMT2A 4469/4885MAPT 330/4885L3MBTL1 4453/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885MAPT 562/4885L3MBTL1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.